The Indian Council of Medical Research (ICMR) has unveiled a new framework designed to significantly accelerate the ethics approval process for clinical research across India. This initiative, known as the Single Ethics Review (SER) model, aims to eliminate bottlenecks and inefficiencies that have historically plagued multi-centre studies.
Streamlining Multi-Centre Research Approvals
Under the previous system, each hospital or institution involved in a clinical trial was required to conduct its own independent ethical review of the same study protocol. This often led to extensive delays, duplicative submissions, and a considerable waste of resources, particularly for research spanning multiple states and institutions.
The ICMR observed that these repeated reviews frequently resulted in inconsistencies and inefficiencies without offering substantial additional protection to research participants. Furthermore, ethics committees often found themselves engaged in coordination tasks rather than focusing on core ethical oversight.
The New Single Ethics Review (SER) Model
The SER framework, introduced as an addendum to ICMR’s National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017, revolutionizes this process. Now, a single, designated Ethics Committee will have the authority to approve a clinical study on behalf of all participating sites.
A coordinating principal investigator will submit a common proposal to this designated committee, which will then undertake the comprehensive review, issue a consolidated decision, and oversee ongoing monitoring, protocol deviations, and adverse event reporting across all participating locations.
Eligibility and Scope
To qualify as a designated ethics committee under the SER model, committees must meet specific eligibility criteria, including having trained members, robust digital infrastructure, and prior experience in managing large multicentre studies.
The framework encompasses a broad spectrum of biomedical and health research. This includes clinical trials for drugs, vaccines, biologics, and medical devices, as well as genomic studies, epidemiological research, public health surveys, and studies involving health data and biological samples. However, regulatory clinical trials will continue to adhere to the existing Drugs and Cosmetics Act and the New Drugs and Clinical Trial Rules, 2019.
Benefits and Participant Protection
The ICMR anticipates that the SER mechanism will not only streamline the ethical review process but also enhance participant protection and regulatory compliance. A key benefit is the expected increase in participation from underserved and geographically remote populations in clinical research.
Field units, community health centres, and outreach locations that previously faced barriers to participating in multicentre studies due to the absence of their own ethics committees can now engage under the approval of a central committee. This expansion is crucial for generating more representative evidence, which is vital for informed healthcare policy and treatment decisions.
Despite the move towards a centralized approval mechanism, the ICMR emphasizes that participant safety, informed consent, privacy safeguards, and continuous monitoring will remain paramount throughout the review process.